McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports

McKesson and Clayton, Dubilier & Rice (CD&R) are moving forward with a deal to acquire Option Care Health. According to coverage from the Wall Street Journal, Yahoo Finance, and Axios, the transaction is valued at $5.8 billion. The acquisition is designed to take the at-home infusion therapy provider private, a detail specifically highlighted in reporting from Reuters. The deal represents a significant consolidation in the healthcare services sector as these two entities combine resources to bring Option Care Health under their control. The coverage of this transaction is widespread across several major financial and news outlets. Reuters has provided multiple reports, including one noting that the Financial Times originally reported the entities were nearing a deal worth more than $5 billion.

The Wall Street Journal and Yahoo Finance have both confirmed the specific $5.8 billion figure. Additionally, Axios has reported that the acquisition cost is around $5.8 billion, while Investor's Business Daily noted that the strike of this deal has resulted in one stock skyrocketing, though the specific ticker was not named in the headlines. To understand the context of this move, it is necessary to identify the nature of the target company. Option Care Health is identified across the reporting as a provider of at-home infusion therapy. This specialization in home-based medical care is the primary focus of the acquisition. The involvement of CD&R, a private equity firm, alongside a major healthcare company like McKesson, indicates a strategic effort to privatize a company that specializes in delivering complex medical treatments outside of a traditional hospital or clinical setting.

Observers will be monitoring the finalization of the $5.8 billion agreement. Based on the reporting from Reuters, the primary objective is to take the infusion therapy provider private. Future updates will likely focus on the official closing of the deal and any subsequent changes to the corporate structure of Option Care Health. Coverage from Investor's Business Daily suggests that market reactions have already begun, as evidenced by the mention of a skyrocketing stock price following the announcement of the $5.8 billion arrangement.